gliclazide has been researched along with Insulin Resistance in 26 studies
Gliclazide: An oral sulfonylurea hypoglycemic agent which stimulates insulin secretion.
Insulin Resistance: Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In this study, we used the frequently sampled intravenous glucose tolerance test (FSIGT) to evaluate the insulin sensitivity (IS), glucose sensitivity (SG), and acute insulin response after glucose load (AIRg) after 4 months treatment with either gliclazide or repaglinide." | 9.14 | Comparison of insulin sensitivity, glucose sensitivity, and first phase insulin secretion in patients treated with repaglinide or gliclazide. ( Chu, YM; Hsia, TL; Hsiao, FC; Hsieh, AT; Lee, LH; Lin, JD; Pei, C; Pei, D; Wang, K; Wu, CZ, 2010) |
| "To investigate the effect of insulin and gliclazide therapy on endoplasmic reticulum (ER) stress and insulin sensitivity in the liver of type 2 diabetic rats." | 7.78 | [The effects of insulin and gliclazide therapy on endoplasmic reticulum stress and insulin sensitivity in liver of type 2 diabetic rats]. ( Bi, Y; Cai, MY; Chen, X; Liang, H; Liao, LZ; Sun, WP; Weng, JP; Zhu, YH, 2012) |
| " In this study, we investigated whether gliclazide, a second-generation sulfonylurea, can protect 3T3L1 adipocytes from insulin resistance induced by oxidative stress, and whether gliclazide can restore insulin-stimulated glucose transporter 4 (GLUT4) translocation under oxidative stress." | 7.73 | Gliclazide protects 3T3L1 adipocytes against insulin resistance induced by hydrogen peroxide with restoration of GLUT4 translocation. ( Ishida, H; Ito, E; Katahira, H; Katsuta, H; Nagamatsu, S; Ohno, H; Seki, H; Shimoyama, T; Takahashi, K; Ushikawa, K; Yamaguchi, S; Yoshimoto, K, 2006) |
| "Adult patients with type 2 diabetes controlled with insulin frequently require the addition of insulin sensitising drugs such as metformin and sometimes glitazones to achieve optimum glycaemic control." | 5.33 | Is it time to re-assess the role of gliclazide? Targeting insulin resistance in type 2 diabetes patients suboptimally controlled with insulin. ( Brown, N, 2006) |
| " In this study, we used the frequently sampled intravenous glucose tolerance test (FSIGT) to evaluate the insulin sensitivity (IS), glucose sensitivity (SG), and acute insulin response after glucose load (AIRg) after 4 months treatment with either gliclazide or repaglinide." | 5.14 | Comparison of insulin sensitivity, glucose sensitivity, and first phase insulin secretion in patients treated with repaglinide or gliclazide. ( Chu, YM; Hsia, TL; Hsiao, FC; Hsieh, AT; Lee, LH; Lin, JD; Pei, C; Pei, D; Wang, K; Wu, CZ, 2010) |
| "As compared with the patients receiving insulin monotherapy, the patients taking metformin alone or in combination showed a more effective recovery of carbohydrate and lipid metabolic disturbances, diminished insulin resistance (IR), lowered blood pressure and albuminuria, reduced diastolic dysfunction, and a smaller cardiovascular risk." | 5.14 | [Capabilities of hypoglycemic therapy in women with decompensated type 2 diabetes mellitus]. ( Elsukova, OS; Onuchin, SG; Onuchina, EL; Solov'ev, OV, 2010) |
| "To investigate the effect of insulin and gliclazide therapy on endoplasmic reticulum (ER) stress and insulin sensitivity in the liver of type 2 diabetic rats." | 3.78 | [The effects of insulin and gliclazide therapy on endoplasmic reticulum stress and insulin sensitivity in liver of type 2 diabetic rats]. ( Bi, Y; Cai, MY; Chen, X; Liang, H; Liao, LZ; Sun, WP; Weng, JP; Zhu, YH, 2012) |
| " In this study, we investigated whether gliclazide, a second-generation sulfonylurea, can protect 3T3L1 adipocytes from insulin resistance induced by oxidative stress, and whether gliclazide can restore insulin-stimulated glucose transporter 4 (GLUT4) translocation under oxidative stress." | 3.73 | Gliclazide protects 3T3L1 adipocytes against insulin resistance induced by hydrogen peroxide with restoration of GLUT4 translocation. ( Ishida, H; Ito, E; Katahira, H; Katsuta, H; Nagamatsu, S; Ohno, H; Seki, H; Shimoyama, T; Takahashi, K; Ushikawa, K; Yamaguchi, S; Yoshimoto, K, 2006) |
| "We evaluated insulin resistance and assessed the effect of gliclazide on insulin resistance in a patient with diabetes mellitus associated with Turner's syndrome." | 3.69 | Insulin resistance in a patient with diabetes mellitus associated with Turner's syndrome. ( Hashimoto, K; Hisatake, K; Kumon, Y; Suehiro, T; Sumiyoshi, R, 1994) |
| "The primary aim must be the treatment of the insulin resistance." | 2.43 | [Controversial therapeutic strategies in the treatment of type 2 diabetes mellitus]. ( Schumm-Draeger, PM, 2005) |
| " Physiological and treatment-related factors were evaluated as potential influential covariates using a population pharmacokinetic modeling approach (NONMEM version 7." | 1.62 | Effect of Nigella sativa oil on pharmacokinetics and pharmacodynamics of gliclazide in rats. ( Adiwidjaja, J; Sasongko, L, 2021) |
| "Approximately 40% of patients with type 2 diabetes may progress to nephropathy and a good metabolic control can prevent the development of diabetic renal injury." | 1.37 | Insulin and metformin may prevent renal injury in young type 2 diabetic Goto-Kakizaki rats. ( da Cunha, FX; Louro, TM; Matafome, PN; Nunes, EC; Seiça, RM, 2011) |
| " Long-term use of metformin in complex multifactorial therapy of women with decompensated type 2 diabetes DM, AH and abdominal obesity provides improvement of carbohydrate and lipid metabolism, lowering of arterial pressure, diminishment of albuminuria, diastolic dysfunction, and stiffness of left ventricular myocardium." | 1.36 | [Dynamics of structural-functional parameters of cardiovascular system during use of complex therapy of women with type 2 diabetes mellitus]. ( Elsukova, OS; Onuchin, SG; Onuchina, EL; Solov'ev, OV, 2010) |
| "Effective long-term treatment of Type 2 Diabetes Mellitus (T2DM) implies modification of the disease processes that cause this progressive disorder." | 1.33 | A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying Type 2 Diabetes Mellitus. ( Danhof, M; de Winter, W; DeJongh, J; Eckland, D; Moules, I; Ploeger, B; Post, T; Urquhart, R, 2006) |
| "Adult patients with type 2 diabetes controlled with insulin frequently require the addition of insulin sensitising drugs such as metformin and sometimes glitazones to achieve optimum glycaemic control." | 1.33 | Is it time to re-assess the role of gliclazide? Targeting insulin resistance in type 2 diabetes patients suboptimally controlled with insulin. ( Brown, N, 2006) |
| "Treatment with gliclazide could not restore p38 phosphorylation in insulin-resistant cells." | 1.31 | Gliclazide increases insulin receptor tyrosine phosphorylation but not p38 phosphorylation in insulin-resistant skeletal muscle cells. ( Dey, CS; Kumar, N, 2002) |
| "Gliclazide was given to group A following CSII, and to five obese NIDDM patients (group B) in their habitual hyperglycemic state." | 1.28 | Effect of 6-month gliclazide treatment on insulin release and sensitivity to endogenous insulin in NIDDM: role of initial continuous subcutaneous insulin infusion-induced normoglycemia. ( Cerasi, E; del Rio, G; Della Casa, L; Glaser, B, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (11.54) | 18.7374 |
| 1990's | 5 (19.23) | 18.2507 |
| 2000's | 11 (42.31) | 29.6817 |
| 2010's | 6 (23.08) | 24.3611 |
| 2020's | 1 (3.85) | 2.80 |
| Authors | Studies |
|---|---|
| Adiwidjaja, J | 1 |
| Sasongko, L | 1 |
| Konya, H | 1 |
| Hasegawa, Y | 1 |
| Hamaguchi, T | 1 |
| Satani, K | 1 |
| Umehara, A | 1 |
| Katsuno, T | 1 |
| Ishikawa, T | 1 |
| Miuchi, M | 1 |
| Kohri, K | 1 |
| Suehiro, A | 1 |
| Kakishita, E | 1 |
| Miyagawa, J | 1 |
| Namba, M | 1 |
| Wu, CZ | 1 |
| Pei, D | 1 |
| Hsieh, AT | 1 |
| Wang, K | 1 |
| Lin, JD | 1 |
| Lee, LH | 1 |
| Chu, YM | 1 |
| Hsiao, FC | 1 |
| Pei, C | 1 |
| Hsia, TL | 1 |
| Onuchin, SG | 2 |
| Elsukova, OS | 2 |
| Solov'ev, OV | 2 |
| Onuchina, EL | 2 |
| Louro, TM | 1 |
| Matafome, PN | 1 |
| Nunes, EC | 1 |
| da Cunha, FX | 1 |
| Seiça, RM | 1 |
| Sun, WP | 1 |
| Bi, Y | 1 |
| Liang, H | 1 |
| Cai, MY | 1 |
| Chen, X | 1 |
| Zhu, YH | 1 |
| Liao, LZ | 1 |
| Weng, JP | 1 |
| Kumar, N | 1 |
| Dey, CS | 1 |
| Khan, M | 1 |
| Xu, Y | 1 |
| Edwards, G | 1 |
| Urquhart, R | 2 |
| Mariz, S | 1 |
| Schumm-Draeger, PM | 1 |
| Inukai, K | 1 |
| Watanabe, M | 1 |
| Nakashima, Y | 1 |
| Sawa, T | 1 |
| Takata, N | 1 |
| Tanaka, M | 1 |
| Kashiwabara, H | 1 |
| Yokota, K | 1 |
| Suzuki, M | 1 |
| Kurihara, S | 1 |
| Awata, T | 1 |
| Katayama, S | 1 |
| Satoh, J | 1 |
| Takahashi, K | 2 |
| Takizawa, Y | 1 |
| Ishihara, H | 1 |
| Hirai, M | 1 |
| Katagiri, H | 1 |
| Hinokio, Y | 1 |
| Suzuki, S | 1 |
| Tsuji, I | 1 |
| Oka, Y | 1 |
| Perriello, G | 1 |
| Pampanelli, S | 1 |
| Di Pietro, C | 1 |
| Brunetti, P | 1 |
| de Winter, W | 1 |
| DeJongh, J | 1 |
| Post, T | 1 |
| Ploeger, B | 1 |
| Moules, I | 1 |
| Eckland, D | 1 |
| Danhof, M | 1 |
| Shimoyama, T | 1 |
| Yamaguchi, S | 1 |
| Katsuta, H | 1 |
| Ito, E | 1 |
| Seki, H | 1 |
| Ushikawa, K | 1 |
| Katahira, H | 1 |
| Yoshimoto, K | 1 |
| Ohno, H | 1 |
| Nagamatsu, S | 1 |
| Ishida, H | 1 |
| Brown, N | 1 |
| Kumon, Y | 1 |
| Hisatake, K | 1 |
| Suehiro, T | 1 |
| Sumiyoshi, R | 1 |
| Hashimoto, K | 1 |
| Karunakaran, S | 1 |
| Hammersley, MS | 1 |
| Morris, RJ | 1 |
| Turner, RC | 1 |
| Holman, RR | 1 |
| Vestergaard, H | 1 |
| Bratholm, P | 1 |
| Christensen, NJ | 1 |
| Matthews, DR | 1 |
| Hosker, JP | 1 |
| Stratton, I | 1 |
| Della Casa, L | 1 |
| del Rio, G | 1 |
| Glaser, B | 1 |
| Cerasi, E | 1 |
| Chang, TC | 1 |
| Wang, LM | 1 |
| Cheng, CY | 1 |
| Kuo, HF | 1 |
| Liu, PC | 1 |
| Ho, LT | 1 |
| Lesobre, B | 2 |
| Wajchenberg, BJ | 1 |
| Santomaruo, AT | 1 |
| Cherem, JJ | 1 |
| Malerbi, DA | 1 |
| Giurno Filho, A | 1 |
| Lerario, AC | 1 |
| Giannella Neto, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Modulation of Insulin Secretion and Insulin Sensitivity in Bangladeshi Type 2 Diabetic Subjects by an Insulin Sensitizer Pioglitazone and T2DM Association With PPARG Gene Polymorphism.[NCT01589445] | Phase 4 | 77 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | mmol/l (Mean) | |
|---|---|---|
| Baseline FSG | 3rd Month FSG | |
| Metformin ( 002 Group) | 6.2 | 6.5 |
| Pioglitazone (001 Group) | 6.9 | 5.4 |
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | μU/ml (Mean) | |
|---|---|---|
| Baseline FSI | 3rd month FSI | |
| Metformin ( 002 Group) | 13.0 | 13.9 |
| Pioglitazone (001 Group) | 16.2 | 12.3 |
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | percentage (Mean) | |
|---|---|---|
| Baseline HbA1c | 3rd month HbA1c | |
| Metformin ( 002 Group) | 7.8 | 7.0 |
| Pioglitazone (001 Group) | 7.3 | 6.7 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1: Homeostatic Model Assessment of Beta cell function(HOMA percent B) Analysis 2: Homeostatic Model Assessment of Insulin Sensitivity (Homa percent S)" (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | percentage (Mean) | |||
|---|---|---|---|---|
| Baseline HOMA percent beta cells function | 3rd month HOMA percent beta cells function | Baseline HOMA percent sensitivity | 3rd month HOMA percent sensitivity | |
| Metformin ( 002 Group) | 109.3 | 116.0 | 76.2 | 67.2 |
| Pioglitazone (001 Group) | 118.9 | 132.3 | 51.1 | 69.3 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1: Homeostasis Model Assessment Insulin Resistance(HOMA IR) Analysis 2: Quantitative Insulin sensitivity Check Index(QUICKI)" (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | Score on a scale ( SI unit) (Mean) | |||
|---|---|---|---|---|
| Baseline QUICKI | 3rd month QUICKI | Baseline HOMA IR | 3rd month HOMA IR | |
| Metformin ( 002 Group) | 0.57 | 0.54 | 3.7 | 4.3 |
| Pioglitazone (001 Group) | 0.52 | 0.59 | 5.1 | 2.9 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1:Total Cholesterol(TC) Analysis 2:Triglyceride(TG) Analysis 3:High Density Lipoprotein(HDL) Analysis 4:Low Density Lipoprotein(LDL)" (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | mg/dl (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline TC | 3rd month TC | Baseline TG | 3rd month TG | Baseline HDL | 3rd month HDL | Baseline LDL | 3rd month LDL | |
| Metformin (002 Group) | 193.0 | 177.0 | 166.0 | 175.0 | 34.4 | 34.7 | 125.6 | 112.0 |
| Pioglitazone (001 Group) | 182.0 | 178 | 183 | 195 | 33 | 33.2 | 112.8 | 105.5 |
2 reviews available for gliclazide and Insulin Resistance
| Article | Year |
|---|---|
[Controversial therapeutic strategies in the treatment of type 2 diabetes mellitus].
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Follow-Up Studies; Gli | 2005 |
[Physiopathology of non insulin-dependent diabetes. Action of gliclazide].
Topics: Diabetes Mellitus, Type 2; Gliclazide; Humans; Insulin; Insulin Resistance; Insulin Secretion | 1985 |
9 trials available for gliclazide and Insulin Resistance
| Article | Year |
|---|---|
Comparison of insulin sensitivity, glucose sensitivity, and first phase insulin secretion in patients treated with repaglinide or gliclazide.
Topics: Adult; Blood Glucose; Blood Pressure; Body Mass Index; Carbamates; Cross-Over Studies; Diabetes Mell | 2010 |
[Capabilities of hypoglycemic therapy in women with decompensated type 2 diabetes mellitus].
Topics: Blood Glucose; Carbohydrate Metabolism; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug The | 2010 |
Effects of pioglitazone on the components of diabetic dyslipidaemia: results of double-blind, multicentre, randomised studies.
Topics: Adult; Aged; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; | 2004 |
Efficacy of glimepiride in Japanese type 2 diabetic subjects.
Topics: Aged; Asian People; Body Mass Index; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Fe | 2005 |
Secondary sulfonylurea failure: comparison of period until insulin treatment between diabetic patients treated with gliclazide and glibenclamide.
Topics: Age of Onset; Databases, Factual; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glic | 2005 |
Comparison of glycaemic control over 1 year with pioglitazone or gliclazide in patients with Type 2 diabetes.
Topics: Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 2; Double-Blind Method; Female | 2006 |
The Fasting Hyperglycaemia Study: III. Randomized controlled trial of sulfonylurea therapy in subjects with increased but not diabetic fasting plasma glucose.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; England; Fasting; Female; France; Gliclazide; | 1997 |
The physiological action of gliclazide: beta-cell function and insulin resistance.
Topics: Amino Acids; Blood Glucose; Computer Simulation; Diabetes Mellitus, Type 2; Gliclazide; Glucose Clam | 1991 |
The action of gliclazide on insulin secretion and insulin sensitivity in non-obese non-insulin dependent diabetic patients.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Gliclazide; Glucose Tolerance Test; Humans; I | 1990 |
15 other studies available for gliclazide and Insulin Resistance
| Article | Year |
|---|---|
Effect of Nigella sativa oil on pharmacokinetics and pharmacodynamics of gliclazide in rats.
Topics: Animals; Biological Availability; Blood Glucose; Gliclazide; Herb-Drug Interactions; Hyperglycemia; | 2021 |
Effects of gliclazide on platelet aggregation and the plasminogen activator inhibitor type 1 level in patients with type 2 diabetes mellitus.
Topics: Aged; alpha-2-Antiplasmin; Antithrombin III; Azides; Blood Glucose; Body Mass Index; Deoxyuracil Nuc | 2010 |
[Dynamics of structural-functional parameters of cardiovascular system during use of complex therapy of women with type 2 diabetes mellitus].
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Chi-Square Distribution; Data Interpretation, Statis | 2010 |
Insulin and metformin may prevent renal injury in young type 2 diabetic Goto-Kakizaki rats.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dia | 2011 |
[The effects of insulin and gliclazide therapy on endoplasmic reticulum stress and insulin sensitivity in liver of type 2 diabetic rats].
Topics: Animals; Diabetes Mellitus, Experimental; Endoplasmic Reticulum Stress; Gliclazide; Insulin; Insulin | 2012 |
Gliclazide increases insulin receptor tyrosine phosphorylation but not p38 phosphorylation in insulin-resistant skeletal muscle cells.
Topics: Animals; Cell Line; Deoxyglucose; Enzyme Inhibitors; Gliclazide; Hypoglycemic Agents; Imidazoles; In | 2002 |
[2-year data of large clinical comparative studies. Type 2 diabetes: lasting metabolic control with pioglitazone].
Topics: Animals; Clinical Trials as Topic; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drug | 2004 |
A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying Type 2 Diabetes Mellitus.
Topics: Adult; Aged; Algorithms; Blood Glucose; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type | 2006 |
Gliclazide protects 3T3L1 adipocytes against insulin resistance induced by hydrogen peroxide with restoration of GLUT4 translocation.
Topics: 3T3-L1 Cells; Adipocytes; Animals; Gliclazide; Glucose; Glucose Transporter Type 4; Hydrogen Peroxid | 2006 |
Is it time to re-assess the role of gliclazide? Targeting insulin resistance in type 2 diabetes patients suboptimally controlled with insulin.
Topics: Aged; Diabetes Mellitus, Type 2; Female; Gliclazide; Humans; Hypoglycemic Agents; Insulin; Insulin R | 2006 |
Insulin resistance in a patient with diabetes mellitus associated with Turner's syndrome.
Topics: Adult; Diabetes Complications; Diabetes Mellitus; Female; Gliclazide; Glucose Clamp Technique; Gluco | 1994 |
Increments in insulin sensitivity during intensive treatment are closely correlated with decrements in glucocorticoid receptor mRNA in skeletal muscle from patients with Type II diabetes.
Topics: Adult; Aged; Case-Control Studies; Chromatography, High Pressure Liquid; Diabetes Mellitus, Type 2; | 2001 |
Effect of 6-month gliclazide treatment on insulin release and sensitivity to endogenous insulin in NIDDM: role of initial continuous subcutaneous insulin infusion-induced normoglycemia.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Follow-Up Studies; Gliclazide; Humans; Insulin; Insulin In | 1991 |
Effect of gliclazide on non-insulin dependent diabetes mellitus.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Fasting; Gliclazide; Glucose Tolerance Test; Humans; Insul | 1988 |
[Non-insulin-dependent diabetes and gliclazide].
Topics: Diabetes Mellitus, Type 2; Gliclazide; Humans; Insulin; Insulin Resistance; Insulin Secretion; Sulfo | 1986 |